Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer

References

• Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292–306
   PubMed Web of Science ®Google Scholar
• Omur O, Baran Y. An update on molecular biology of thyroid cancers. Crit Rev Oncol/Hematol 2014;90:233–52
   PubMed Web of Science ®Google Scholar
• National Cancer Institute at the National Institutes of Health (database on the Internet). Bethesda (MD): National Cancer. Institute at the National Institutes of Health. 2015. Available from: Available from: http://seer.cancer.gov/statfacts/html/thyro.html [last accessed 27 Mar 2015]
   Google Scholar
• Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2010;16:5936–41
   PubMed Web of Science ®Google Scholar
• Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Mol Genetics 1993;2:851–6
   PubMed Web of Science ®Google Scholar
• Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA: Cancer J Clin 2012;62:283–98
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134–42
   PubMed Web of Science ®Google Scholar
• Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98:E364–9
   PubMed Web of Science ®Google Scholar
• de Groot JW, Plukker JT, Wolffenbuttel BH, et al. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 2006;65:729–36
   PubMed Web of Science ®Google Scholar
• Pellegriti G, Leboulleux S, Baudin E, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 2003;88:1537–42
   PubMed Web of Science ®Google Scholar
• Jaquet AJ. Ein fall von metastasierenden amyloidtumoren (lymphosarcoma). Virchow's Arch A Pathol Anat 1906;185:251–67
   Google Scholar
• Hazard JB, Hawk WA, Crile G. Jr, Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152–61
   PubMed Web of Science ®Google Scholar
• Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966;19:114–18
   PubMed Web of Science ®Google Scholar
• Randolph GW, Maniar D. Medullary carcinoma of the thyroid. Cancer Control 2000;7:253–61
   PubMedGoogle Scholar
• Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol 2013;40:120–33
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol 2013;25:39–43
   PubMed Web of Science ®Google Scholar
• LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997;82:39–41
   PubMed Web of Science ®Google Scholar
• Quayle FJ, Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. Curr Treatment Opt Oncol 2005;6:347–54
   PubMedGoogle Scholar
• Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003;88:2070–5
   PubMed Web of Science ®Google Scholar
• Figlioli G, Landi S, Romei C, et al. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res 2013;752:36–44
   PubMed Web of Science ®Google Scholar
• Brauckhoff M, Machens A, Hess S, et al. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 2008;144:1044–50; discussion 50-3
   PubMed Web of Science ®Google Scholar
• Oberg K. The genetics of neuroendocrine tumors. Semin Oncol 2013;40:37–44
   PubMed Web of Science ®Google Scholar
• Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014;386:2–15
   PubMed Web of Science ®Google Scholar
• Romei C, Cosci B, Renzini G, et al. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol 2011;74:241–7
   PubMed Web of Science ®Google Scholar
• Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658–71
   PubMed Web of Science ®Google Scholar
• American Thyroid Association Guidelines Task F, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565–612
   PubMed Web of Science ®Google Scholar
• Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genetics Med 2011;13:755–64
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K. Genotype–phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo, Brazil) 2012;67:69–75
   PubMed Web of Science ®Google Scholar
• Yeganeh MZ, Sheikholeslami S, Hedayati M. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pacif J Cancer Prev 2015;16:2107–17
   PubMedGoogle Scholar
• Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 2015;25:567–610
   PubMed Web of Science ®Google Scholar
• Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450–5
   PubMed Web of Science ®Google Scholar
• Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173–86
   PubMed Web of Science ®Google Scholar
• Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Eng J Med 2003;349:1517–25
   PubMed Web of Science ®Google Scholar
• Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genetics 2012;205:1–11
   PubMed Web of Science ®Google Scholar
• Wohllk N, Schweizer H, Erlic Z, et al. Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 2010;24:371–87
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581–8
   PubMed Web of Science ®Google Scholar
• Carter MT, Yome JL, Marcil MN, et al. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. Cytogenetics Cell Genetics 2001;95:169–76
   PubMedGoogle Scholar
• Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development (Cambridge, England) 1993;119:1005–17
   PubMed Web of Science ®Google Scholar
• Meng X, Lindahl M, Hyvonen ME, et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science (New York, NY) 2000;287:1489–93
   Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005;16:441–67
   PubMed Web of Science ®Google Scholar
• Colombo-Benkmann M, Li Z, Riemann B, et al. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. Eur J Endocrinol/Eur Feder Endocr Soc 2008;158:811–16
   PubMed Web of Science ®Google Scholar
• de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535–60
   PubMed Web of Science ®Google Scholar
• Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613–19
   PubMed Web of Science ®Google Scholar
• Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12:361–73
   PubMed Web of Science ®Google Scholar
• Garcia-Lavandeira M, Diaz-Rodriguez E, Garcia-Rendueles ME, et al. Functional role of the RET dependence receptor, GFRa co-receptors and ligands in the pituitary. Front Hormone Res 2010;38:127–38
   PubMed Web of Science ®Google Scholar
• Santoro M, Melillo RM, Carlomagno F, et al. Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448–51
   PubMed Web of Science ®Google Scholar
• Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer 2010;9:449–57
   PubMed Web of Science ®Google Scholar
• Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568–76
   PubMed Web of Science ®Google Scholar
• Salehian B, Samoa R. RET gene abnormalities and thyroid disease: who should be screened and when. J Clin Res Pediat Endocrinol 2013;5:70–8
   PubMed Web of Science ®Google Scholar
• Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genetics: TIG 2001;17:580–9
   PubMed Web of Science ®Google Scholar
• Boikos SA, Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histol Histopathol 2008;23:109–16
   PubMed Web of Science ®Google Scholar
• Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682–7
   PubMed Web of Science ®Google Scholar
• Marx SJ, Stratakis CA. Multiple endocrine neoplasia – introduction. J Internal Med 2005;257:2–5
   Web of Science ®Google Scholar
• Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc 1996;276:1575–9
   PubMed Web of Science ®Google Scholar
• Hoff AO, Hoff PM. Medullary thyroid carcinoma. Hematol/Oncol Clin N Am 2007;21:475–88
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Rybicki LA, Erlic Z, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 2011;32:51–8
   PubMed Web of Science ®Google Scholar
• Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005;90:3999–4003
   PubMed Web of Science ®Google Scholar
• Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 2007;142:800–5
   PubMed Web of Science ®Google Scholar
• Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genetics 1994;6:70–4
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005;15:531–44
   PubMed Web of Science ®Google Scholar
• Toledo RA, Hatakana R, Lourenco DM Jr, et al. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr Relat Cancer 2015;22:65–76
   PubMed Web of Science ®Google Scholar
• Iwashita T, Asai N, Murakami H, et al. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 1996;12:481–7
   PubMed Web of Science ®Google Scholar
• Miyauchi A, Futami H, Hai N, et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Resh 1999;90:1–5
   PubMedGoogle Scholar
• Gimm O, Marsh DJ, Andrew SD, et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997;82:3902–4
   PubMed Web of Science ®Google Scholar
• Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res 2015;7:265–78
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer–local disease control in the modern era. Head Neck 2008;30:883–8
   PubMed Web of Science ®Google Scholar
• Lindsey SC, Ganly I, Palmer F, Tuttle RM. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid: Off J Am Thyroid Assoc 2015;25:242–9
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Comprehen Cancer Netw 2014;12:1671–80; quiz 80
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Buhr H, Dralle H, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol/Eur Feder Endocr Soc 2006;155:229–36
   PubMed Web of Science ®Google Scholar
• Daumerie C, Maiter D, Gruson D. Serum calcitonin estimation in medullary thyroid cancer: basal or stimulated levels? Thyroid Res 2013;6:S4
   Google Scholar
• Pina G, Dubois S, Murat A, et al. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Clin Endocrinol 2013;78:358–64
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Therapeut 2011;10:2298–308
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284–90
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Invest Drugs 2007;16:239–49
   PubMed Web of Science ®Google Scholar
• Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009;14:378–90
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010;13:1–14
   PubMed Web of Science ®Google Scholar
• Liu XH, Chen GG, Vlantis AC, van Hasselt CA. Iodine mediated mechanisms and thyroid carcinoma. Crit Rev Clin Lab Sci 2009;46:302–18
   PubMed Web of Science ®Google Scholar
• Maier J, van Steeg H, van Oostrom C, et al. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta 2007;1773:990–9
   PubMed Web of Science ®Google Scholar
• Belfiore A, Russo D, Vigneri R, Filetti S. Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol 2001;55:711–18
   PubMed Web of Science ®Google Scholar
• Boltze C, Brabant G, Dralle H, et al. Radiation-induced thyroid carcinogenesis as a function of time and dietary iodine supply: an in vivo model of tumorigenesis in the rat. Endocrinology 2002;143:2584–92
   PubMed Web of Science ®Google Scholar
• Nishikawa A, Ikeda T, Son HY, et al. Pronounced synergistic promotion of N-bis(2-hydroxypropyl)nitrosamine-initiated thyroid tumorigenesis in rats treated with excess soybean and iodine-deficient diets. Toxicol Sci: Off J Soc Toxicol 2005;86:258–63
   PubMed Web of Science ®Google Scholar
• Williams ED, Abrosimov A, Bogdanova T, et al. Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid: Off J Am Thyroid Assoc 2008;18:847–52
   PubMed Web of Science ®Google Scholar
• Dupuy C, Virion A, Ohayon R, et al. Mechanism of hydrogen peroxide formation catalyzed by NADPH oxidase in thyroid plasma membrane. J Biol Chem 1991;266:3739–43
   PubMed Web of Science ®Google Scholar
• Song Y, Driessens N, Costa M, et al. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab 2007;92:3764–73
   PubMed Web of Science ®Google Scholar
• Ohayon R, Boeynaems JM, Braekman JC, et al. Inhibition of thyroid NADPH-oxidase by 2-iodohexadecanal in a cell-free system. Mol Cell Endocrinol 1994;99:133–41
   PubMed Web of Science ®Google Scholar
• Cardoso LC, Martins DC, Figueiredo MD, et al. Ca(2+)/nicotinamide adenine dinucleotide phosphate-dependent H(2)O(2) generation is inhibited by iodide in human thyroids. J Clin Endocrinol Metab 2001;86:4339–43
   PubMed Web of Science ®Google Scholar
• Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J: Off Publ Feder Am Soc Exp Biol 2003;17:1195–214
   PubMed Web of Science ®Google Scholar
• Kupper FC, Carpenter LJ, McFiggans GB, et al. Iodide accumulation provides kelp with an inorganic antioxidant impacting atmospheric chemistry. Proc Natl Acad Sci US A 2008;105:6954–8
   PubMed Web of Science ®Google Scholar
• McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010;141:210–17
   PubMed Web of Science ®Google Scholar
• Etit D, Faquin WC, Gaz R, et al. Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases. Arch Path Lab Med 2008;132:1767–73
   PubMed Web of Science ®Google Scholar
• Learoyd DL, Gosnell J, Elston MS, et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol 2005;63:636–41
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Theodosopoulos G, Martin-Schulte K, et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1866–72
   PubMed Web of Science ®Google Scholar
• Pai R, Nehru GA, Samuel P, et al. Mutational analysis of RET proto-oncogene among patients with medullary thyroid carcinoma and 'at risk' carriers from India. Clin Endocrinol 2011;75:571–2
   PubMed Web of Science ®Google Scholar
• Abdelhakim A, Barlier A, Kebbou M, et al. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience. J Cancer Res Therapeut 2009;5:198–202
   PubMed Web of Science ®Google Scholar
• Benazzouz B, Hafidi A, Benkhira S, et al. C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family]. Bull Cancer 2008;95:457–63
   PubMed Web of Science ®Google Scholar
• Benazzouz B, Chraibi A, Doghmi Y, et al. Characterization of RET proto-oncogene C634Y mutation in a Moroccan family with multiple endocrine neoplasia type 2A. Ann Endocrinol 2006;67:21–6
   PubMed Web of Science ®Google Scholar
• Sharma BP, Saranath D. RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients. J Biosci 2011;36:603–11
   PubMed Web of Science ®Google Scholar
• Siqueira DR, Romitti M, da Rocha AP, et al. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma. Endocr Relat Cancer 2010;17:953–63
   PubMed Web of Science ®Google Scholar
• Oliveira MN, Hemerly JP, Bastos AU, et al. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid 2011;21:975–85
   PubMed Web of Science ®Google Scholar
• Tamanaha R, Camacho CP, Pereira AC, et al. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. ClinEndocrinol 2009;71:56–64
   PubMed Web of Science ®Google Scholar
• Jindrichova S, Vcelak J, Vlcek P, et al. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004;183:257–65
   PubMed Web of Science ®Google Scholar
• Schuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Human Mol Genetics 1994;3:1939–43
   PubMed Web of Science ®Google Scholar
• Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol: Off J Am Soc Clin Oncol 2006;24:1705–11
   PubMed Web of Science ®Google Scholar
• Guyetant S, Josselin N, Savagner F, et al. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Modern Pathol 2003;16:756–63
   PubMed Web of Science ®Google Scholar
• Goretzki PE, Hoppner W, Dotzenrath C, et al. Genetic and biochemical screening for endocrine disease. World J Surg 1998;22:1202–7
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Hoppner W, Frilling A, et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996;81:1780–3
   PubMed Web of Science ®Google Scholar
• Sarika HL, Papathoma A, Garofalaki M, et al. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece. Clin Endocrinol 2012;77:857–62
   PubMed Web of Science ®Google Scholar
• Kaldrymides P, Mytakidis N, Anagnostopoulos T, et al. A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clin Endocrinol 2006;64:561–6
   PubMed Web of Science ®Google Scholar
• Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, et al. Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res 2011;2011:264248
   PubMedGoogle Scholar
• Alvandi E, Akrami SM, Chiani M, et al. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid: Off J Am Thyroid Assoc 2011;21:373–82
   PubMed Web of Science ®Google Scholar
• Sheikholeslami Sara ZYM, Hoghooghi RL, Ghadaksaz GH, Hedayati M. Haplotype frequency of G691S/S904S in the RET proto-oncogene in patients with medullary thyroid carcinoma. Iran J Public Health 2014;43:235–40
   PubMed Web of Science ®Google Scholar
• Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F. Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia 2006;61:564–9
   PubMedGoogle Scholar
• Ghazi AA, Bagheri M, Tabibi A, et al. Multiple endocrine neoplasia type 2A in an Iranian family: clinical and genetic studies. Arch Iran Med 2014;17:378–82
   PubMed Web of Science ®Google Scholar
• Majidi M, Haghpanah V, Hedayati M, et al. A family presenting with multiple endocrine neoplasia type 2B: a case report. J Med Case Rep 2011;5:587
   PubMedGoogle Scholar
• Zarif Yeganeh M, Sheikholeslami S, Dehbashi Behbahani G, et al. Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. Tumour Biol: J the Int Soc Oncodev Biol Med 2015;36:5225–31
   PubMed Web of Science ®Google Scholar
• Romei C, Mariotti S, Fugazzola L, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol/Eur Feder Endocr Soc 2010;163:301–8
   PubMed Web of Science ®Google Scholar
• Shifrin AL, Ogilvie JB, Stang MT, et al. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation. Surgery 2010;148:1274–80; discussion 80-1
   PubMed Web of Science ®Google Scholar
• Kameyama K, Okinaga H, Takami H. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 2004;58:345–7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Yebra B, Medrano ME, Mantilla A, et al. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation. Endocr Pathol 2003;14:71–80
   PubMed Web of Science ®Google Scholar
• Chung YJ, Kim HH, Kim HJ, et al. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid 2004;14:813–18
   PubMed Web of Science ®Google Scholar
• Jung J, Uchino S, Lee Y, Park H. A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation. J Korean Med Sci 2010;25:226–9
   PubMed Web of Science ®Google Scholar
• Prazeres HJ, Rodrigues F, Figueiredo P, et al. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol 2006;64:659–66
   PubMed Web of Science ®Google Scholar
• Bugalho MJ, Domingues R, Santos JR, et al. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 2007;141:90–5
   PubMed Web of Science ®Google Scholar
• Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009;100:1777–83
   PubMed Web of Science ®Google Scholar
• Silva AL, Carmo F, Moura MM, et al. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. Endocrine 2015
   Web of Science ®Google Scholar
• Moore SW, Zaahl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET. Pediatr Surg Int 2008;24:521–30
   PubMed Web of Science ®Google Scholar
• Moore SW, Zaahl MG. Chasing the ubiquitous RET proto-oncogene in South African MEN2 families–implications for the surgeon. S Afr J Surg Suid-Afrikaanse tydskrif vir chirurgie 2010;48:127–31
   Google Scholar
• Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg 2007;42:326–32
   PubMed Web of Science ®Google Scholar
• Wohllk N, Becker P, Youlton R, Cote GJ, et al. Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chile 2001;129:713–18
   PubMed Web of Science ®Google Scholar
• Belli S, Storani ME, Dourisboure RJ. Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers. Medicina 2003;63:41–5
   Google Scholar
• Milos IN, Frank-Raue K, Wohllk N, et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC > TGG) mutation. Endocr Relat Cancer 2008;15:1035–41
   PubMed Web of Science ®Google Scholar
• Sanchez Sobrino P, Paramo Fernandez C, Gil Gil P, et al Phenotype of the C634Y mutation in the RET proto-oncogene in MEN2A: report of a family. Endocrinol Nutrn: Org Soc Espan Endocrinol Nutr 2011;58:229–35
   Google Scholar